Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents

Med Res Rev. 2003 Nov;23(6):657-68. doi: 10.1002/med.10050.

Abstract

Human cytochrome P450 (CYP)1B1 is a major enzyme for carcinogenic estrogen metabolism and involved in the metabolic activation of procarcinogens of the polycyclic aromatic hydrocarbons (PAHs). CYP1B1 is known to be expressed at a high frequency in various human cancers, but not in normal tissues. It also plays an important role in the metabolism of various anti-cancer drugs. These findings suggest inhibition of CYP1B1 as a new oncological therapeutic strategy. Several natural and synthetic compounds have been studied in an effort to find the isoform-specific inhibitors of the CYP1 subfamily. A survey of the inhibitors of CYP1B1 and other related inhibitors of the CYP1 subfamily is provided in this review.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors*
  • Aryl Hydrocarbon Hydroxylases / pharmacology*
  • Cytochrome P-450 CYP1B1
  • Female
  • Forecasting
  • Humans
  • Male
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Sensitivity and Specificity
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents
  • Aryl Hydrocarbon Hydroxylases
  • CYP1B1 protein, human
  • Cytochrome P-450 CYP1B1